multicentre trials
Recently Published Documents


TOTAL DOCUMENTS

119
(FIVE YEARS 14)

H-INDEX

22
(FIVE YEARS 2)

Author(s):  
R Bhome ◽  
D Karavias ◽  
T Armstrong ◽  
Z Hamady ◽  
A Arshad ◽  
...  

This article reports on the first series of patients to receive intraoperative radiotherapy for pancreatic cancer in the UK. The data suggest that this treatment modality is feasible and safe, laying a platform for collaborative multicentre trials to better assess efficacy.


2021 ◽  
Vol 108 (3) ◽  
pp. 231-232
Author(s):  
M Sund

Abstract In the March issue of BJS several hot topics within the breast surgery field are highlighted in beautifully planned and executed prospective multicentre trials. BJS encourages the surgical communities in most fields to move towards prospective collaborative and multicentre studies, thereby increasing both power and generalizability as well as reducing the risk of bias.


Author(s):  
Massimiliano M Marrocco-Trischitta ◽  
Mattia Glauber

Abstract Contemporary guidelines on thoracic aortic repair provide inconsistent reporting standards for the definition of aortic arch classification in Types I, II and III. The different reported criteria cannot be used interchangeably, due to a very low level of concordance, and this finding has relevant implications for the comparisons between studies using different classifications, and between different datasets of multicentre trials, which are not consistently analyzed with the same criteria. Also, the reported definitions, which were originally proposed for predicting difficult carotid stenting and therefore were conceived for healthy aortic arches, can be influenced by the pathological derangements of the aortic wall, including aneurysms and dissections. In this respect, the Madhwal’s classification, which is based on the diameter of the left common carotid artery, appears to be the more suitable one for aortic arch classification in patients with thoracic aortic disease because it provides relevant clinical information along with an adequate reproducibility.


2021 ◽  
Vol 33 (2) ◽  
pp. 125-130
Author(s):  
M. Lassmann ◽  
U. Eberlein ◽  
J. Tran-Gia

2020 ◽  
Vol 21 (12) ◽  
pp. 1320-1330
Author(s):  
Riemer H J A Slart ◽  
Andor W J M Glaudemans ◽  
Olivier Gheysens ◽  
Mark Lubberink ◽  
Tanja Kero ◽  
...  

Abstract With this summarized document we share the standard for positron emission tomography (PET)/(diagnostic)computed tomography (CT) imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is) as recently published in the European Journal of Nuclear Medicine and Molecular Imaging. This standard should be applied in clinical practice and integrated in clinical (multicentre) trials for optimal standardization of the procedurals and interpretations. A major focus is put on procedures using [18F]-2-fluoro-2-deoxyglucose ([18F]FDG), but 4Is PET radiopharmaceuticals beyond [18F]FDG are also described in this summarized document. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicentre trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. Diagnosis and management of 4Is related cardiovascular diseases are generally complex and often require a multidisciplinary approach by a team of experts. The new standards described herein should be applied when using PET/CT and PET/magnetic resonance, within a multimodality imaging framework both in clinical practice and in clinical trials for 4Is cardiovascular indications.


2020 ◽  
Vol 30 (11) ◽  
pp. 1566-1571
Author(s):  
Mariam Zaidi ◽  
Nilofer Sorathia ◽  
Hannah Abbasi ◽  
Arwa Khashkhusha ◽  
Amer Harky

AbstractThe ductus arteriosus (DA) connects the pulmonary artery to the aorta to bypass the pulmonary circulation in utero. It normally closes within 24–72 hours after birth due to increased pulmonary resistance from an increase in oxygen partial pressure with the baby’s first breath. Medical treatment can help close the DA in certain situations where closure is delayed. However, in duct-dependent cardiac defects, the presence of the DA is crucial for survival and as such medical and surgical techniques have evolved to prevent closure. This review aims to outline the two main management options for keeping a ductus arteriosus patent. This includes stenting the PDA and shunting via a modified Blalock–Taussig shunt. Whilst both techniques exist, multicentre trials have found equal mortality end points but significantly reduced morbidity with stenting than shunting. This is also reflected by shorter recovery times, reduced requirement for extracorporeal membrane oxygenation (ECMO), and improved quality of life, although stent longevity remains a limiting factor.


2020 ◽  
Vol 19 (4) ◽  
pp. 602-607 ◽  
Author(s):  
Clare Saunders ◽  
Renee Jensen ◽  
Paul D. Robinson ◽  
Sanja Stanojevic ◽  
Michelle Klingel ◽  
...  

2019 ◽  
Vol 41 (10) ◽  
pp. 1123-1131 ◽  
Author(s):  
Christian Sohns ◽  
Nassir F Marrouche

Abstract The understanding of atrial fibrillation (AF) evolved from a sole rhythm disturbance towards the complex concept of a cardiomyopathy based on arrhythmia substrates. There is evidence that atrial fibrosis can be visualized using late gadolinium enhancement cardiac magnetic resonance imaging and that it is a powerful predictor for the outcome of AF interventions. However, a strategy of an individual and fibrosis guided management of AF looks promising but results from prospective multicentre trials are pending. This review gives an overview about the relationship between cardiac fibrosis and AF focusing on translational aspects, clinical observations, and fibrosis imaging to emphasize the concept of personalized paths in AF management taking into account the individual amount and distribution of fibrosis.


Sign in / Sign up

Export Citation Format

Share Document